Literature DB >> 8620414

High grade soft tissue sarcoma of the flexor fossae. Size rather than compartmental status determine prognosis.

R S Yang1, J M Lane, F R Eilber, F J Dorey, R al-Shaikh, L Y Schumacher, G Rosen, C A Forscher, J J Eckardt.   

Abstract

BACKGROUND: High grade soft tissue sarcoma arising in the popliteal space, axilla, and antecubital fossae (flexor fossae tumors) have by convention been classified as extracompartmental tumors by the accepted staging and grading criteria of the Musculoskeletal Tumor Society (MSTS). Advances in neoadjuvant chemotherapy and radiation therapy have made surgical resection more feasible. The hypothesis to be tested is that compartmental status may not be of prognostic significance if the tumor is adjusted for size, histologic grade, and distant metastasis after undergoing adjuvant chemotherapy and radiation.
METHODS: From June 1976 to December 1992, 22 patients with high grade soft tissue sarcomas of the flexor fossae (Group A) were treated at UCLA Medical Center. The histologic subtypes were liposarcoma (five), synovial cell sarcoma (eight), malignant fibrous histiocytoma (four), leiomyosarcoma (two), angiosarcoma (two), and rhabdomyosarcoma (one). The popliteal fossa was the location in 11, the axilla in 10, and the antecubital fossa in 1. Wide resection was attempted in all patients after preoperative chemotherapy and radiation therapy. Amputation was performed in 5 patients because of repeated or extensive recurrent tumor. A group of 77 patients (Group B) with high grade soft tissue sarcoma located within an extremity compartment were chosen to test the hypothesis that survival of patients with tumors in the flexor fossae is equal to that of patients with intracompartmental tumors of similar size and grade if both are given adjuvant therapy. This group was chosen so that histologic subtype, size, sex, and location would be similar in the two groups. The authors selected thigh and calf tumors for comparison with popliteal fossa tumors and periscapular, deltoid, and arm tumors for comparison with axilla and antecubital fossae tumors. All of these patients had similar treatment and follow-up protocols. The median follow-up of survivors in Group A was 104 months and for patients in Group B was 79 months.
RESULTS: The 5-year cumulative survival rate (Kaplan-Meier method) of patients in Group A was 76%, and 67% for those in Group B. The difference was not significant. Three patients in Group A (14%) and 17 (22%) in Group B had local tumor recurrence. Eight patients in Group A (36%) and 27 (35%) in Group B had lung metastases. Age, sex, histologic subtype, and surgical margins did not affect survival outcomes, lung metastasis, and local recurrence. However, patients with larger tumors (maximum dimension > or = 8 cm or cross-sectional area > or = 40 cm2) had significantly poorer survival, more metastases, and local recurrences.
CONCLUSION: Flexor fossae sarcomas do not have a poorer prognosis than extremity intracompartmental tumors when adjusted for size, distant metastasis, and histologic grade when they are treated with adjuvant radiation therapy, chemotherapy, and surgery.

Entities:  

Mesh:

Year:  1995        PMID: 8620414     DOI: 10.1002/1097-0142(19951015)76:8<1398::aid-cncr2820760815>3.0.co;2-b

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

1.  Preoperative Planning Using Three-Dimensional Multimodality Imaging for Soft Tissue Sarcoma of the Axilla: A Pilot Study.

Authors:  Xiang Fang; Yan Xiong; Fang Yuan; Senlin Lei; Dechao Yuan; Yi Luo; Yong Zhou; Li Min; Wenli Zhang; Chongqi Tu; Hong Duan
Journal:  Cancers (Basel)       Date:  2022-06-29       Impact factor: 6.575

2.  Outcomes in patients with popliteal sarcomas.

Authors:  Robert E Turcotte; Marco Ferrone; Marc H Isler; Cynthia Wong
Journal:  Can J Surg       Date:  2009-02       Impact factor: 2.089

3.  Prognostic impact of peritumoral lymphocyte infiltration in soft tissue sarcomas.

Authors:  Sveinung W Sorbye; Thomas K Kilvaer; Andrej Valkov; Tom Donnem; Eivind Smeland; Khalid Al-Shibli; Roy M Bremnes; Lill-Tove Busund
Journal:  BMC Clin Pathol       Date:  2012-02-29

4.  Prognostic impact of CD57, CD68, M-CSF, CSF-1R, Ki67 and TGF-beta in soft tissue sarcomas.

Authors:  Sveinung W Sorbye; Thomas K Kilvaer; Andrej Valkov; Tom Donnem; Eivind Smeland; Khalid Al-Shibli; Roy M Bremnes; Lill-Tove Busund
Journal:  BMC Clin Pathol       Date:  2012-05-03

5.  The prognostic impact of TGF-β1, fascin, NF-κB and PKC-ζ expression in soft tissue sarcomas.

Authors:  Andrej Valkov; Sveinung W Sorbye; Thomas K Kilvaer; Tom Donnem; Eivind Smeland; Roy M Bremnes; Lill-Tove Busund
Journal:  PLoS One       Date:  2011-03-03       Impact factor: 3.240

6.  Prognostic impact of lymphocytes in soft tissue sarcomas.

Authors:  Sveinung W Sorbye; Thomas Kilvaer; Andrej Valkov; Tom Donnem; Eivind Smeland; Khalid Al-Shibli; Roy M Bremnes; Lill-Tove Busund
Journal:  PLoS One       Date:  2011-01-27       Impact factor: 3.240

7.  The prognostic impact of Akt isoforms, PI3K and PTEN related to female steroid hormone receptors in soft tissue sarcomas.

Authors:  Andrej Valkov; Thomas K Kilvaer; Sveinung W Sorbye; Tom Donnem; Eivind Smeland; Roy M Bremnes; Lill-Tove Busund
Journal:  J Transl Med       Date:  2011-11-22       Impact factor: 5.531

8.  Extended resection including adjacent organs and Ki-67 labeling index are prognostic factors in patients with retroperitoneal soft tissue sarcomas.

Authors:  Yosuke Morizawa; Makito Miyake; Keiji Shimada; Shunta Hori; Yoshihiro Tatsumi; Yasushi Nakai; Satoshi Anai; Nobumichi Tanaka; Noboru Konishi; Kiyohide Fujimoto
Journal:  World J Surg Oncol       Date:  2016-02-24       Impact factor: 2.754

9.  Prognostic impact of Jab1, p16, p21, p62, Ki67 and Skp2 in soft tissue sarcomas.

Authors:  Sveinung W Sorbye; Thomas K Kilvaer; Andrej Valkov; Tom Donnem; Eivind Smeland; Khalid Al-Shibli; Roy M Bremnes; Lill-Tove Busund
Journal:  PLoS One       Date:  2012-10-05       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.